Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

2020, Volume 14, Issue 2

Abstract

Keywords

Related Research

Back to Top

Frontiers of Medicine >> 2020, Volume 14, Issue 2 doi: 10.1007/s11684-020-0750-4

Development of oncolytic virotherapy: from genetic modification to combination therapy

. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai 200032, China.. Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China.. Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

Accepted: 2020-03-09 Available online: 2020-03-09
HTML19 PDF 3 Collect 0

Next Previous

Abstract

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and safety have been genetically modified, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Related Research